Amgen files suit against F. Hoffmann-LaRoche, alleging infringement of Epogen patents

By E. Janene Geiss

Philadelphia, Nov. 9 - Amgen said Wednesday that it filed a lawsuit in the U.S. District Court in Boston against F. Hoffmann-LaRoche Ltd., Roche Diagnostics GmbH and Hoffmann-LaRoche, Inc., seeking declaration by the court that the defendants' importation, use, sale or offer to sell a pegylated version of recombinant human erythropoietin infringes on Amgen's patents.

Amgen alleges infringement of six U.S. patents owned by Amgen that claim erythropoietin products and pharmaceutical compositions and processes for making erythropoietin products, according to a company news release.

Amgen seeks a permanent injunction preventing the defendants from making, importing, using, offering for sale or selling recombinant human erythropoietin products, including pegylated erythropoietin products, in the United States, officials said.

Amgen markets Epogen, a recombinant human erythropoietin product, in the United States for the treatment of anemia associated with chronic renal failure for patients on dialysis.

Amgen, a Thousand Oaks, Calif.-based biotechnology company, focuses on discovery of human therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.